News | February 10, 2026
SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
The company’s EBITDA margin remained resilient above 20%
The company’s EBITDA margin remained resilient above 20%
HCG clinicians contributing to one of the largest bodies of oncology research from India
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
Hologic has been at the forefront of cervical cancer screening for decades
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Subscribe To Our Newsletter & Stay Updated
